The first 60 days: Desmoid tumour
Desmoid tumours are locally aggressive growths of fibroblast-like cells, driven by WNT pathway mutations, that never spread to distant organs but can invade nerves, bowel and muscle. A substantial fraction stop growing or shrink on their own, so watching first is standard; for those that progress, the gamma-secretase inhibitor nirogacestat, approved in 2023, shrinks tumours and relieves pain. Below, week by week, is what OnCo's record of Desmoid tumour says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
- Newly diagnosed, asymptomatic or minimally symptomaticNCCN category Category 2A (observation), Desmoid Tumor Working Group consensus (Eur J Cancer 2020); NCCN Soft Tissue Sarcoma
Active surveillance with MRI at 1 to 2 months, then every 3 to 6 months; treat only on progression or symptoms.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Newly diagnosed, asymptomatic or minimally symptomatic.
- RadiologistNamed in the standard of care for: Newly diagnosed, asymptomatic or minimally symptomatic.
- SurgeonNamed in the standard of care for: Newly diagnosed, asymptomatic or minimally symptomatic, Surgery.
- Medical oncologistNamed in the standard of care for: Progressive or symptomatic disease.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
- 1.Surgery
Reserved for selected abdominal wall tumours or complications (bowel obstruction, fistula); margins do not reliably predict recurrence.
- 2.Progressive or symptomatic diseaseNCCN category Category 1 (nirogacestat), Category 2A (sorafenib), NCCN Soft Tissue Sarcoma
Nirogacestat (DeFi) or sorafenib (Alliance A091105); alternatives include methotrexate-vinblastine, vinorelbine, anthracycline-based chemotherapy for rapidly progressive disease, and cryoablation for accessible extra-abdominal tumours.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example CTNNB1 mutation type, Germline APC testing when intra-abdominal or multifocal, Nuclear beta-catenin immunostaining, MRI T2 signal, Symptom and pain scores), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Sporadicdesmoid, FAP-associateddesmoid, often intra-abdominal, Abdominal wall desmoid.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Newly diagnosed, asymptomatic or minimally symptomatic
- For my situation (newly diagnosed, asymptomatic or minimally symptomatic), which of the standard options do you recommend and why?Guideline options include: Active surveillance with MRI at 1 to 2 months, then every 3 to 6 months; treat only on progression or symptoms.
Progressive or symptomatic disease
- For my situation (progressive or symptomatic disease), which of the standard options do you recommend and why?Guideline options include: Nirogacestat (DeFi) or sorafenib (Alliance A091105); alternatives include methotrexate-vinblastine, vinorelbine, anthracycline-based chemotherapy for rapidly progressive disease, and cryoablation for accessible extra-abdominal tumours.
- Am I a candidate for Nirogacestat, Sorafenib, Methotrexate, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of DeFi apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Surgery
- For my situation (surgery), which of the standard options do you recommend and why?Guideline options include: Reserved for selected abdominal wall tumours or complications (bowel obstruction, fistula); margins do not reliably predict recurrence.
Any stage
- Are there clinical trials I could join, for example of Nirogacestat, Intermittent or stop-and-restart nirogacestat in desmoid tumours, DeFi, Varegacestat?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Ovarian toxicity of gamma-secretase inhibitors in young women: dose interruption and intermittent schedules are being explored”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Optimal treatment duration and whether responses persist after stopping nirogacestat”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- A Study of AL102 in Patients With Progressing Desmoid TumorsPhase 2/3 · active · NCT04871282RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors
- A Study in Adults With Desmoid TumorsPhase 2 · recruiting · NCT07541430An Open-Label, Multicenter, Single-Arm Phase 2 Study of ES014 in Adult Subjects With Desmoid Tumors
- A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)Phase 2 · active · NCT07170644A Single-arm, Open-label Phase 2 Study of Nirogacestat in Adult Japanese Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Desmoid tumour: the full pageDesmoid tumours are locally aggressive growths of fibroblast-like cells, driven by WNT pathway mutations, that never spread to distant organs but can invade nerves, bowel and muscle. A substantial fraction stop growing or shrink on their own, so watching first is standard; for those that progress, the gamma-secretase inhibitor nirogacestat, approved in 2023, shrinks tumours and relieves pain.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Rare cancers: Rare cancers are those with fewer than about 6 new cases per 100,000 people per year.
Every term links to the glossary.